Staar Surgical cuts 25% of jobs in restructuring
This article was originally published in Clinica
Ophthalmic company Staar Surgical is to slash its workforce by 25% and consolidate its manufacturing and distribution operations in an attempt to become profitable on operations by early 2002. It will also make several changes in its top management (see below). The company will take a total of $12 million in charges over the next several quarters as a result.
You may also be interested in...
Lannett will launch a further seven products in fiscal 2021, after launching four products recently in the first quarter of FY21. The company also plans to pay off its Term Loan ‘A’ in full, by the end of November 2020.
Pfizer has now received a formal European Commission approval for its Nyvepria biosimilar pegfilgrastim. The approval puts the firm in direct competition with several other versions of the Neulasta original.
AstraZeneca's research head admits that the half dose approach was a lucky mistake - but one that could boost the vaccine's effectiveness and supplies. The US regulator may not be persuaded, however.